A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors
Clinical trial NCT04826341 · COMPLETED
Trial details
- NCT number
- NCT04826341
- Sponsor
- National Cancer Institute (NCI)
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-09-20
- Primary completion
- 2026-05-20
- Enrollment
- 35
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.